摘要
Studies have shown that dysregulated expression of miRNAs is a major underlying event in the onset and progression of many metabolic diseases.The pathological role of miR-548c-3p in various cancer types,including breast cancer,glioma,prostate cancer,and gastric cancer,has been documented.1 However,experimental evidences validating the role of miR-548c-3p in the development of metabolic diseases are still lacking,and no data is available on its diagnostic potential for metabolic syndrome(MS).Recently,we predicted the involvement of miR-548c-3p in the pathogenesis of MS and its progression to cardiovascular diseases(CVD)via the regulation of target genes necessary for the proper function of insulin resistance,mTOR,and JAK/STAT signaling pathways.2 Therefore,we deemed it necessary to engage in wet laboratory analysis and validate these claims in patients with metabolic syndrome compared to healthy individuals.
